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ABSTRACT
We compared the donation of bone marrow (BM) versus recombinant human granulocyte colony-stimulating
factor–mobilized peripheral blood progenitor cells (PBPC) in HLA-matched sibling donors. Donors random-
ized to donate BM or PBPC completed questionnaires (Profile of Mood States [POMS] and Short-Form 36
Health Survey) assessing peridonation health-related quality of life (QoL), donation experience, and accept-
ability of donation before and 1 week and 4 weeks after donation. Between January 1996 and March 1999, 184
patients and their donors were randomized. Predonation and postdonation data were available on 52 (56%) and
35 (38%) of the BM and PBPC donors, respectively. The median donor age was 45 years, and 44% were female.
The median time (range) to return to full activity for the BM and PBPC donors was 4 days (1-21 days) and 2
days (0-21 days), respectively (P  .01). One week after donation, BM donors reported more fatigue and less
energy than the PBPC donors. BM donors’ POMS total mood disturbance scores were worse 1 week after
versus before donation, whereas the PBPC donors’ scores did not change. POMS subscores indicated more
fatigue and less energy in the BM versus PBPC donors. Anxiety improved in both groups, but more in PBPC
donors. Four weeks after donation, the Short-Form 36 Health Survey indicated persistent moderate negative
effects on QoL with BM donation versus small effects with PBPC donation. BM donation was associated with
more physical morbidity and negative effects on QoL up to 1 month after donation than was PBPC donation.
Despite this, most donors would donate again. Further work is needed to decrease donor anxiety and
symptoms. If both BM and PBPC donation are feasible, then the graft source should be dictated by the
predicted patient outcome as determined from the results of randomized trials.
© 2004 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
Allogeneic bone marrow (BM) transplantation is
he treatment of choice for several malignant and
B&MTonmalignant hematologic diseases. Recently, there
as been increasing interest in the use of cytokine-
obilized peripheral blood progenitor cells (PBPC),
ather than BM, from related and unrelated donors for405
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4he reconstitution of hematopoiesis after myeloabla-
ive therapy [1-5]. In adults, HLA-matched related
llogeneic PBPCs result in faster neutrophil and plate-
et engraftment without an increased incidence of
cute graft-versus-host disease (GVHD) [6-11]. Their
se may also be associated with lower costs during the
ransplantation and initial follow-up period [12,13].
uestions remain regarding the incidence and sever-
ty of chronic GVHD, its associated costs, and its
ffects on quality of life (QoL), as well as the appro-
riate clinical settings in which to use PBPC instead of
M as the graft source. A number of randomized trials
nd comparative studies addressing these and other
elated issues have been reported [7-9,11,12,14].
With the increasing use of PBPC transplantation,
ssues that concern the donor have also come to the
ore. There are signiﬁcant procedural differences be-
ween donating BM and PBPC. Although BM dona-
ion is safe [15], it does entail a general or spinal
nesthetic, discomfort at the harvest site, and potential
hort-term loss of productivity. PBPC donation re-
uires the donor to receive recombinant human gran-
locyte colony-stimulating factor (rhG-CSF) and un-
ergo apheresis. Concerns have been raised regarding
ide effects and the short- and long-term safety of
hG-CSF administration [16-18]. A workshop involv-
ng more than 40 transplant centers worldwide put
orth recommendations regarding these donor issues
19].
In addition to the known procedural differences
nd presumed associated symptoms, other important
ssues that have not received as much attention are the
sychosocial and longer-term postdonation physical
ffects on the volunteer that could have implications
egarding the acceptability of donating PBPC. Al-
hough there have been reports on the experience of
M donation [15,20-22], few studies have directly
ompared the donation of BM and PBPC [17,23-26].
Starting in January 1996, the Canadian Bone Mar-
ow Transplant Group (CBMTG) undertook a mul-
icenter randomized trial comparing PBPC with BM
n patients undergoing a matched or 1 antigen–mis-
atched sibling donor allogeneic transplantation for
cute myeloid leukemia, chronic myeloid leukemia, or
yelodysplastic syndrome. In an attempt to address
he paucity of information regarding the donor expe-
ience, a component of this trial was a donor experi-
nce study. This study collected data to better under-
tand the effects of donating BM or PBPC and to
ompare the donor experience in terms of morbidity
nd QoL.
ATIENTS AND METHODS
tudy Design
This study was conducted as a component of the
BMTG multicenter trial comparing the use of rhG- m
06SF–mobilized PBPC transplants with BM trans-
lants from matched or 1 antigen–mismatched sibling
onors in the treatment of patients with acute myeloid
eukemia, chronic myeloid leukemia, or myelodysplas-
ic syndrome [11]. Eligible donor and recipient pairs
ere registered with the central data center, where
andomization to 1 of the 2 treatment arms was per-
ormed. Randomization was stratiﬁed by center and
ecipient disease. Each center’s research ethics board
pproved the study. Donors gave written, informed
onsent to participate in the CBMTG trial, including
he donor experience study.
onor Eligibility Criteria
Donors were siblings of the recipient, with a 5/6
r 6/6 HLA match. Eligible donors had to be consid-
red ﬁt to undergo both BM harvest and PBPC col-
ection. Exclusion criteria for the donors were inabil-
ty to undergo a general anesthetic, pregnancy or
actation, history of a malignant disease or current
alignancy other than nonmelanomatous in situ skin
arcinoma or cervical carcinoma in situ, human im-
unodeﬁciency virus positivity, known sensitivity to
scherichia coli–derived products, and being the iden-
ical twin sibling of the recipient.
tem Cell Collection Methods
Donors randomized to donate PBPC were given
hG-CSF (5-8 g/kg/d) for 4 consecutive days by
ubcutaneous injection administered by himself/her-
elf, by a family member, or by a nurse. The dose was
djusted by weight: donors 60, 60 to 90, and 90 kg
ere given 300, 480, and 600 g/d, respectively. Leu-
apheresis collections were performed on the fourth
nd ﬁfth days of rhG-CSF. Counts of mononuclear
ells, CD34-positive cells, and CD3-positive cells
ere performed on each day’s collection. If there were
ewer than 2.5  106 CD34 cells per kilogram recip-
ent weight in the combined leukapheresis product,
he donor underwent a standard BM harvest, and this,
ogether with the PBPC collection, was given to the
ecipient. Leukapheresis was usually undertaken by
sing peripheral venous access; if this was not possible,
central venous catheter was inserted at the discretion
f the attending physician in consultation with the
onor to complete the leukapheresis. If this was nec-
ssary, speciﬁc consent for the placement of a central
enous catheter was obtained.
Donors randomized to donate BM underwent
arvest from both posterior iliac crests (as well as the
nterior crests and sternum if necessary) under general
r regional anesthesia. A minimum yield of 2  108
ucleated cells per kilogram recipient weight was the
arget harvest; however, no more than 1400 mL of
arrow was removed from the donor.
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Donor Experience in a Multicenter Randomized Controlled Trial
Bonor Assessment
Assessment of the donor with regard to proce-
ure-related symptoms, peridonation health-related
oL, and acceptability of the donation of BM or
BPC was performed by using predonation and post-
onation questionnaires completed by the donor. The
redonation assessment was given to the donor after
onsent to the trial and after randomization to BM
arvest or PBPC collection. Donors were asked to
omplete the questionnaires while at clinic or within
4 hours of consenting to participate in the study.
eturn-addressed, stamped envelopes were supplied
o the donors who wished to complete the question-
aires at home within the 24-hour period. The pre-
onation questionnaires consisted of a demographics
age, a short form of the Proﬁle of Mood States
POMS) [27,28], a Short-Form 36 Health Survey (SF-
6) [29,30], and a section requesting a narrative of
oncerns or comments.
The donor was given a second questionnaire
ooklet and a return-addressed, postage-paid enve-
ope before discharge after the donation of BM or
BPC with instructions on when and how to complete
he questionnaires. The second set of questionnaires
as a repeat of the short form of the POMS at 1 week
nd the SF-36 at 4 weeks after donation. In addition,
questionnaire to be ﬁlled out at 1 week contained
rocedure-speciﬁc questions regarding the donation
f either BM or PBPC. Donors were asked about their
illingness to donate again and, on a 7-point scale,
hether the experience had been much better (1)
hrough much worse (7) than expected. They were
iven the opportunity to describe the most difﬁcult
spect of donation and to comment on the experience
n general and the adequacy of predonation informa-
ion. Donors were also asked about the number of
ays before return to full activities after donation and
hether they saw a physician after discharge from the
ollecting center. This questionnaire also listed, in a
ikert scale format, symptoms speciﬁc to either form
f donation, and donors were asked to grade them
rom no symptoms (1) to extremely severe symptoms
7). They were also asked to comment on which of the
isted symptoms had been the most disabling. Patients
ho were required to undergo both a PBPC collection
nd a BM harvest because of an inadequate stem cell
ollection were asked to ﬁll out a postdonation pro-
edure-speciﬁc questionnaire that included questions
elated to the donation of both BM and PBPC. Each
enter was responsible for distributing and collecting
heir donors’ questionnaires, including follow-up via
hone or mail of late or missing questionnaires. The
entral study coordinator notiﬁed participating cen-
ers of overdue responses. In addition to phone con-
act, if necessary, a letter requesting completion of the
utstanding form was sent to donors, along with the s
B&MTequired questionnaires and a return-addressed, post-
ge-paid envelope.
oL Assessment Tools
The POMS linear analog self-assessment (POMS-
ASA) is a simple, rapid self-report questionnaire that
onsists of a 6 linear analog scale measuring tool that
as derived, with good correlation, from the longer
OMS, a 65-item 5-point adjective self-rating scale
27,28]. In the POMS-LASA, 6 factors are assessed:
atigue, anxiety, confusion, depression, energy/vigor,
nd anger. The LASA scale takes the form of a 10-cm
ine with each end anchored by phrases describing
olar opposites of the item under consideration (ie, 1
nd with “not at all [anxious]” and the other end with
extremely [anxious]”). Patients are asked to place a
ertical mark on each scale at a position that best
escribes his or her state during a speciﬁed period.
he score for each item is determined by measuring in
illimeters from the end of the scale that represents
he absence of a symptom. A total mood disturbance
TMD) score can be calculated by summing the scores
f the 6 LASA scales with energy weighted negatively.
herefore, scores can range from 100 (best possible
core) to 500 (worst possible score).
The SF-36 [29,30] is a generic indicator of health
tatus derived from the 245-item Medical Outcomes
tudy questionnaire [29,30]. The SF-36 includes
ulti-item scales to measure the following 8 dimen-
ions: physical functioning, role limitations due to
hysical health problems (RP), bodily pain (BP), gen-
ral health perception, vitality (VT), social function-
ng, role limitations due to emotional problems, and
eneral mental health. The scoring system for each
imension uses an approach that recodes the answers
f each question into a 0 to 100 score, which is ori-
nted so that a higher score indicates a better health
tate. For example, functioning scales are scored such
hat a high score indicates better functioning, and the
ain scale is scored such that a higher score indicates
ecreased pain.
tatistical Analysis
Comparison of baseline data was performed by
sing the 2 test for categorical data and by parametric
ethods (Student t test) or nonparametric methods
Mann-Whitney test) if the normality conditions of
he sample were not assured for continuous data. For
he QoL questionnaires, the changes from before to
fter donation were determined for each group by
sing the scoring guidelines for each of the tools. The
egree of change was compared between the 2 groups
y using the Student t test. Cohen’s effect size [31] was
etermined by dividing the mean delta score for a
omain subscore by the standard deviation (SD) of the
ame group’s baseline scores. Although the exact in-
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4erpretation of effect-size values is not universally
greed on, the effect size is a useful tool to estimate
he clinical signiﬁcance of changes measured with a
oL tool. It “adjusts” or “modulates” the delta by the
egree of variability in responses between individuals
s measured by the SD of the baseline scores. Cohen
as proposed that an effect size of 0.2 is not mean-
ngful, that 0.2 to 0.5 is small, that 0.5 to 0.8 is
oderate, and that 0.8 is large [29]. Effect sizes for
hange from baseline to after donation were calculated
or both the POMS and the SF-36 responses. By
ooking at the results for the BM and PBPC donors,
he differences in effect size are an indication of the
elative degree of clinical change from before to after
onation, even if this is not taken as an absolute
easure. Exploratory univariate analyses of correla-
ion between changes in QoL and demographic fea-
ures were undertaken. Statistical analysis was per-
ormed with the statistical analysis software GraphPad
RISM version 2.0 (GraphPad Software, San Diego,
A).
ESULTS
onors
From January 1996 to March 1999, 184 sibling
onors were randomized to donate either BM or
BPC. Ninety-three and 91 donors were randomized
able 1. Donor Demographics
haracteristic
Before Donation
BM (n  93) PBPC
ge (y)
Median 45
Range 15-74 21
ex (%)
Female 45
Male 55
n
arital status 1 y before donation/at donation (%)
Single
Married
Living with partner
Separated
Divorced
Widowed
evel of education (%)
Less than high school graduate
High school graduate
Technical school graduate
University graduate
Postgraduate university studies
Seven donated both BM and PBPC and were excluded from postd
Number of donors who answered postdonation questionnaires.
Number of donors who answered the characteristics portion of tho the BM and PBPC groups, respectively. Responses t
08o the predonation characteristics portion of the de-
ographics questionnaire were received from 76
82%) and 55 (60%) of the BM and PBPC donors,
espectively. Responses to postdonation procedure-
elated questionnaires and predonation and postdona-
ion POMS and SF-36 were received by 52 (56%) and
5 (38%) of BM and PBPC donors, respectively. An
dditional 7 donors (4%) initially randomized to the
BPC group were required to donate BM as well
ecause of an inadequate number of CD34-positive
ells collected with 2 leukaphereses. Postdonation
uestionnaires for this group were not ﬁlled out prop-
rly; therefore, these donors were excluded from sub-
equent analysis. The median age, sex, marital status,
nd educational level of the donors are described in
able 1. There were no signiﬁcant differences in the
emographic characteristics of the BM and the PBPC
onors. There were no signiﬁcant differences in age,
ex, marital status, or educational level in donors who
ubmitted the postdonation questionnaires compared
ith those who did not. Responders were equally
istributed across centers.
redonation Concerns
Predonation concerns or comments were reported
y 32 (45%) and 21 (42%) of the responding BM and
BPC donors, respectively. Some donors had more
han 1 concern or comment. The most common
After Donation
) BM (n  52)† PBPC* (n  35)†
45 44
23-63 21-67
42 40
58 60
n  50‡ n  52† n  35†
22 13 22
66 71 66
2 10 3
2 4 3
6 2 6
2 0 0
26 23 20
22 34 29
26 23 20
14 12 23
12 8 8
n analysis (see text).
graphics questionnaire.(n  91
44
-67
43
57
 71‡
23
63
7
6
1
0
24
34
24
11
7
onatio
e demoheme expressed by both the BM (n  16) and the
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Donor Experience in a Multicenter Randomized Controlled Trial
BBPC (n  10) donors was related to the overall
utcome or speciﬁc aspects of the transplantation ex-
erience for the recipient. Five PBPC donors ex-
ressed speciﬁc concerns regarding the experimental
ature of the PBPC transplants. Small numbers of
atients in both groups identiﬁed concerns related to
he short-term side effects, inconveniences, or poten-
ial toxicities of the donation process.
M and PBPC Collection
For the BM harvest, all but 2 donors underwent a
eneral anesthetic. One donor underwent a spinal
nesthetic and 1 an epidural anesthetic. The PBPC
ollection was performed with a peripheral venous
ine in all donors save 2, in whom a central venous line
as required for adequate apheresis.
onor Assessment before and 1 Week and 4
eeks after Donation
Procedure-Related Questions, 1 Week after Donation.
able 2 presents donor answers to procedure-related
uestions. BM donors took more days to return to full
ctivity (median, 4 days) compared with PBPC donors
median, 2 days). Both BM and PBPC donors felt that
he donation process had been better than expected
median, 2 and 1, respectively), and most donors in
able 2. Procedure-Speciﬁc Questions
Question
BM
(n  52)*
PBPC
(n  35)*
P
Value†
illing to donate again? (%)
Yes 42 (81) 25 (71) NS
No 2 (4) 0
Don’t know 8 (15) 10 (29)
edian number of days to full
activity (min/max) 4 (1/21) 2 (0/21) 0.01
edian; better/worse than
expected (min/max)‡ 2 (1/7) 1 (1/6) <.05
ut-of-pocket expense (%)
No expense 11 (21) 8 (23) NS
<$100 9 (17) 8 (23)
$100-$500 15 (29) 11 (31)
>$500 17 (33) 8 (23)
eed to see physician after
donation (%)
Yes§ 9 (17) 5 (14) NS
No 43 (83) 30 (86)
dequate information given? (%)
Yes 47 (90) 30 (86) NS
No 5 (10) 5 (14)
Number of donors who completed the questionnaire.
Signiﬁcant when P  .05; NS indicates not signiﬁcant.
Donors asked to circle 1 number from 1 to 7: 1  better, 7 
worse.
See text for symptoms reported.
See text for donor reasons.oth groups stated that they would donate again. Out- B
B&MTf-pocket expenses, as reported by donors, were not
ifferent.
There was no difference between groups regard-
ng the proportion of donors who saw a physician after
onation. Nine BM donors (17%) saw a physician for
he following reasons (some donors had more than 1
eason): pain at the harvest site (n  4), routine fol-
ow-up (n  2), general malaise (n  2), fever (n  1),
heck harvest wound (n  1), odynophagia (n  1),
heck blood pressure (n 1), and anemia (n 1). The
orresponding reasons given by the 5 (14%) PBPC
onors were routine follow-up to verify blood counts
n  5), fatigue (n  1), and bone pain (n  1).
Postdonation concerns or comments were re-
orted by 32 (62%) and 23 (66%) of the BM and
BPC donors, respectively. Some donors had more
han 1 concern or comment. Approximately one third
f each group expressed positive feelings related to the
onation experience and their care. In both the BM
nd the PBPC groups, negative comments were sim-
lar in nature to concerns expressed in their predona-
ion questionnaires and related mostly to physical or
sychological aspects of the donation process.
The severity of symptoms related to the donation
f BM or PBPC was graded on a scale of 1 (not severe)
o 7 (extremely severe). Both groups graded the symp-
oms of “fatigue” and “lack of energy,” whereas other
ymptoms were not identically worded because of the
ifferences between collection procedures. BM do-
ors experienced worse fatigue and lack of energy 1
eek after donation compared with the PBPC donors.
edian (range) ratings of fatigue for the BM and
BPC donors were 3 (1-7) and 2 (1-7) (P  .01), and
or lack of energy they were 4 (1-7) and 2 (1-7) (P 
01), respectively.
Both groups were asked which of the listed symp-
oms had been the most disabling. Some donors re-
orted more than 1 most disabling symptom. The
ost common BM donor responses were stiffness in
he pelvic bones (n 15), fatigue (n  13), pain in the
elvic bones (n 9), and lack of energy (n 7). Other
ymptoms reported by the BM donors were headache
n  3), chills (n  1), odynophagia (n  1), pruritus
n  1), generalized aches (n  1), and back pain (n 
). Seven BM donors reported no disabling symptoms.
he PBPC donor responses to most disabling symp-
oms were bone pain (n  13), fatigue (n  5), un-
leasant reaction (such as chills, shakes, cramps, or
ausea) while donating (n 3), lack of energy (n 2),
ain or irritation at rhG-CSF injection site (n  2),
ain or stiffness from placement of a central venous
ine (n  2), pain or stiffness in arms from peripheral
enous lines (n 1), and joint pains (n 1). Six PBPC
onors reported no disabling symptoms.
Most donors in both groups reported being well
nformed about the donation procedure. The 5 (10%)
M donors and 5 (14%) PBPC donors who did not
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4eel well informed identiﬁed a lack of general proce-
ural information and a lack of explanation of poten-
ial side effects and complications as the deﬁciency.
espite the information being present in the donor
onsent form, 1 patient in the PBPC group expressed
oncern about being unaware of the potential need for
onation of both PBPC and BM in the event that
BPC collection was unsuccessful.
QoL Assessment: POMS at Baseline and 1 Week after
onation. To compare the predonation and postdona-
ion scores, analysis was performed only on donors
ho had answered both the predonation and postdo-
ation POMS questionnaires. Forty-eight BM donors
51%) and 33 PBPC donors (36%) completed the
OMS both before and after donation.
The mean TMD scores of the BM and PBPC
onors were not signiﬁcantly different either before or
fter donation. Although the TMD scores (mean 
D) for the BM donors were statistically worse after
onation (51.2  64.5) than before donation (25.2 
8.3; P  .02), the magnitude of the difference was
mall. The predonation (34.5  88.5) and postdona-
ion (33.9  88.2) TMD scores for the PBPC donors
ere not signiﬁcantly different.
Although the overall scores for the POMS were
ot markedly different, individual scores and the de-
ree of change varied markedly between donors. To
xplore this, the effect sizes (mean change in score/
roup baseline SD) [31] for the change from baseline
o 1 week after donation for each of the 6 mood states
ere calculated and are summarized in Figure 1. Both
he BM and PBPC groups identiﬁed increased fatigue
nd decreased energy after donation, but more fatigue
nd less energy were reported by the BM donors
ompared with the PBPC donors. PBPC donors also
xperienced a greater decrease in anxiety than BM
onors at 1 week after donation. Only PBPC donors
xperienced a decrease in confusion after donation.
Figure 1. POMS: Change from before donatiohe remainder of the mood states did not have sig- f
10iﬁcant effect-size ratings, suggesting no signiﬁcant
hange from before to 1 week after donation.
To verify the POMS effect-size data, a semiquan-
itative analysis was also performed on the degree of
hange between predonation and postdonation indi-
idual mood states in relation to the TMD scores, and
esults were compared with the effect-size analysis. A
elta of 50 between the predonation and postdona-
ion TMD scores was considered to be clinically sig-
iﬁcant for an individual. A change in the TMD score
f 50 was chosen because of published data that sug-
est that a decrease of approximately 10% in the
OMS score for a general population can separate
eople with normal performance status from those
ith signiﬁcant disability [29,30]. Donors were
rouped on the basis of whether their TMD scores
ad increased by 50 (clinical worsening), decreased
y 50 (clinical improvement), or changed 50 (a
linically insigniﬁcant change). The numbers of BM
onors whose TMD score signiﬁcantly worsened, im-
roved, or did not change signiﬁcantly were 21 (44%),
(12%), and 21 (44%), respectively. The numbers of
BPC donors whose TMD score signiﬁcantly wors-
ned, improved, or did not change signiﬁcantly were 9
27%), 8 (24%), and 16 (49%), respectively. In both
roups, there were no identiﬁable differences in de-
ographic characteristics and procedure-related re-
ponses among donors whose TMD scores worsened,
mproved, or remained unchanged.
For both groups, analysis of donors whose delta
core had increased or decreased by 50 from before
o after donation was performed on individual mood
tates. Similar results were found in both the BM and
BPC donors. The results of this analysis correlated
ith the effect-size data: donors whose TMD score
ncreased by 50 (clinical worsening) had fatigue and
nergy identiﬁed as the individual mood states that
orsened by the greatest amount (median change:
week after donation as measured by effect size.n to 1atigue, 40 and 45; energy, 27 and 33 [negative
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Balues for energy indicate decreasing energy] for the
M and PBPC donors, respectively). For this group,
nxiety, confusion, depression, and anger scores also
orsened, but to lesser degrees. Again, in keeping
ith the effect-size analysis, donors whose TMD
core decreased by 50 (clinical improvement) had
nxiety as the identiﬁed individual mood state that
mproved most, with a median change of 42.5 and
34 for the BM and PBPC donors, respectively. For
his group, fatigue, confusion, depression, anger, and
nergy scores also improved, but to lesser degrees.
QoL Assessment: SF-36 at Baseline and at 4 Weeks
fter Donation. Fifty-one BM donors (55%) and 31
BPC donors (34%) responded to both the predona-
ion and postdonation SF-36 questionnaires. The
ean scale score for the individual dimensions is pre-
ented in Table 3. There was no difference in predo-
ation scores between the BM and PBPC donors for
ost postdonation dimension scores, including phys-
cal functioning, general health, VT, social function-
ng, role limitations due to emotional problems, and
ental health. Scores for RP and BP, however, were
ower for BM donors than for PBPC donors 4 weeks
fter donation (Table 3).
There were also differences when comparing pre-
onation and postdonation scores within the BM or
BPC groups. The effect size for change from base-
ine to 4 weeks after donation for each of the individ-
al dimensions was calculated. In the BM group, sig-
iﬁcant effect-size ratings were identiﬁed for 5 of the
dimensions, with 3 of them either large (RP effect
ize, 1.1; BP effect size, 0.86) or moderate (VT
ffect size, 0.78). All 5 domains that had signiﬁcant
ffect sizes indicated worsening from before to 4
eeks after donation for the BM group. In contrast,
he PBPC group had small (4) or nonsigniﬁcant (4)
ffect size ratings for all 8 dimensions. In the PBPC
roup, the small effect-size rating for mental health
ndicated some improvement—a ﬁnding in keeping
able 3. SF-36 Dimension Scores
Dimension*
Be
BM (n  51)
hysical functioning 88.5
ole limitation due to physical health problems 94.1
odily pain 85.9
eneral health perception 83.2
itality 73.2
ocial functioning 89
ole limitations due to emotional problems 92.2
eneral mental health 79.7
The mean score for individual SF-36 dimensions.
Signiﬁcant when P  .05; NS indicates not signiﬁcant.ith the POMS results described previously. [
B&MTISCUSSION
This study compared the physical and psycholog-
cal effects of donating hematopoietic stem cells in
onors randomly assigned to provide either BM or
BPC. The results indicate that BM donors experi-
nced more short- and moderate-term physical and
sychological morbidity after donation than the
BPC donors. Both donor groups had similar appre-
ensions before donation, with most expressing con-
erns regarding symptom anticipation and manage-
ent. In addition, however, approximately 25% of
BPC donors were worried about the experimental
ature of the transplantation and possible ramiﬁca-
ions for the recipient. By asking donors to join a study
n which they may not bear the ultimate consequences
f their decision to participate (eg, GVHD or death),
here is the potential for putting them at increased risk
f negative feelings, such as guilt, should the experi-
ental transplant have a poor outcome. This could be
iewed as an extension of the reported effect of recip-
ent outcome on the donor [32].
During the ﬁrst week after donation, BM donors
equired more time to return to full activity, experi-
nced more fatigue, and had less energy and more
ain than the PBPC donors. Both groups experienced
ymptoms similar to those previously reported
14,16,17,23-25,33,34], primarily pain or stiffness,
ith a longer duration in the BM donors. The SF-36
esults at 4 weeks after donation in our study, how-
ver, indicated more persistent impairment in BM
onors than has previously been reported.
Increased physical morbidity in the BM donor
roup persisted up to 4 weeks after donation. The
F-36 results indicated signiﬁcant limitations related
o RP and BP for BM donors compared with PBPC
onors. At 4 weeks after donation, BM donors had
cores for RP and BP that were below the norms of
he general US population [30] and were similar to
cores of patients with chronic medical conditions
onation After Donation
(n  31) P Value† BM (n  51) PBPC (n  31) P Value†
7.9 NS 88.1 89.1 NS
2.5 NS 59.3 81.7 <.05
0.4 NS 70.5 80.4 .03
1.9 NS 80.9 76.8 NS
4.5 NS 58.3 65.7 NS
7.9 NS 80.5 90 NS
9.2 NS 83.7 89.3 NS
1.3 NS 81.8 84.1 NSfore D
PBPC
8
9
8
8
7
8
8
829]. This decline in physical health is not negligible.
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4ata from the Medical Outcomes Study show that
pproximately 13% of surveyed patients with mean
cores similar to the 4-week-postdonation scores in
he BM donors were unable to work because of health
roblems. In contrast, the PBPC donors had no post-
onation scores below general population norms. The
bservation of increased physical morbidity in the BM
onors was also evident in the results of the effect-size
nalysis. Although the duration of physical disability
dentiﬁed by the SF-36 was signiﬁcant, most BM do-
ors reported being able to return to full activity by 1
eek after donation.
Heldal et al. [34] reported results for 61 subjects
andomized to donate either BM or PBPC. Although
M donors reported more initial discomfort and re-
ated physical limitations after donation, the mean
otal symptom scores for the 2 groups were the same
s of 4 days after donation, and discomfort scores were
he same as of 5 days after donation. Rowley et al. [24]
eported on the physical effects of donation in 69
ubjects studied as part of a randomized allogeneic
M versus PBPC trial. The ﬁndings of their study
ere similar to ours regarding the nature, intensity,
nd period of peak symptomatology, although they
id not identify physical effects extending out to 28
ays. This may reﬂect the different measurement tools
n the 2 studies. More recently, Nishimori et al. [22]
eported similar physical symptoms measured with the
F-36 in volunteer unrelated BM donors in Japan at 1
eek after donation, with resolution by 3 months after
onation.
The effects of the donation process on donor
ood also favored the PBPC group. Although both
roups had signiﬁcant effect-size ratings for worsen-
ng fatigue and energy level, the magnitude of these
hanges was greater in the BM donors, whereas anx-
ety decreased more in the PBPC donors. This paral-
eled a decrease in confusion in PBPC donors after
onation. These changes likely reﬂected a better un-
erstanding of the newer experimental donation pro-
edure and resolution of related anxiety, as indicated
n some donors’ comments. Fortanier [33] noted a
imilarly heightened level of anxiety in PBPC donors
efore donation that resolved quickly once aphereses
ere initiated. Our analysis, based on improvement or
orsening of POMS scores by 50, supports the
F-36 results and the POMS effect-size analysis in
hat individuals who worsened clinically after dona-
ion tended to do so because of increased fatigue and
oss of energy, whereas those who improved did so
ecause of decreased anxiety. Further studies elucidat-
ng factors that inﬂuence donor reaction are necessary
o better prepare donors. Because physical morbidity
an affect mood, it is possible that improved predo-
ation education regarding symptom anticipation and
anagement would reduce anxiety and improve the
verall donor experience. e
12Switzer et al. [25] reported the results of a survey
f 79 volunteer donors from the National Marrow
onor Program who had donated twice, including 30
ubjects who had donated BM initially and then, at
ome later time, PBPC. PBPC donors displayed some
esitancy toward their second donation, measured as a
igher likelihood to postpone the decision to donate.
his was not seen in the BM group. Nonetheless, in
ur study and the other studies in which it was asked,
he vast majority of donors indicated they would be
illing to donate again [25,34].
Despite characterizing the donor experience and
dentifying several differences between the BM and
BPC donors, our study has a number of limitations
hat should be addressed in future studies. Although
he assessment tools included validated QoL mea-
ures, the timing and frequency of their administra-
ion leave gaps in our knowledge. We did not expect
o see signiﬁcant physical morbidity or QoL changes
n donors at 4 weeks after donation. In retrospect, for
M donors and, to a lesser degree, PBPC donors,
mpairment remains at this time point, and an addi-
ional assessment at 3 months after donation would
ave helped to deﬁne what proportion of donors had
rolonged symptoms that affected their QoL. This
ould be useful to better inform donors and to po-
entially modify clinical follow-up of donors. Simi-
arly, it would also have been informative to adminis-
er the POMS at 1 month and, potentially, 3 months
fter transplantation to better characterize the emo-
ional effects of donating. It may have also allowed us
o study the relationship between recipient morbidity
nd mortality and donor QoL. In retrospect, our at-
empt to capture donor symptoms was also somewhat
iased because our questionnaires focused on symp-
oms that we were expecting and differed somewhat
etween the BM and PBPC donors. We would have
een better able to compare the experience had we
ncluded a more comprehensive symptom list for both
roups, even if we expected that some would be absent
or 1 group or the other. Donor experience is more
omplicated than we anticipated, and our design was
ompromised by our misconceptions. Including a
ore comprehensive psychological assessment tool or
ormal interview process and longer follow-up would
ikely have yielded a more comprehensive understand-
ng of the donor experience.
A more difﬁcult issue to explain is the low per-
entage of donors who responded to the question-
aires despite consenting to the study. Only 60% of
he PBPC donors completed the initial forms, versus
2% of BM donors. Of those who completed the
nitial forms, the proportion that completed the sub-
equent forms was similar: 70% of PBPC and 73% of
M donors. Several limitations of the study that may
ave contributed to the low response rates do not
xplain differential participation by PBPC and BM
d
s
i
t
c
U
r
t
c
p
v
d
c
s
m
f
p
t
h
s
e
h
f
u
t
d
m
s
i
t
p
t
r
m
u
t
s
p
c
S
p
g
i
A
s
m
c
n
p
b
f
w
b
r
e
t
r
w
r
w
r
o
r
r
g
v
ﬁ
e
w
p
g
A
t
d
R
Donor Experience in a Multicenter Randomized Controlled Trial
Bonors. Because this was an unfunded multicenter
tudy, we did not have the opportunity to have an
nvestigators’ meeting to train coordinators or inves-
igators on consent procedures or on methods to fa-
ilitate participation in the donor experience study.
pon review, it seems that the donor participation
ate improved over time (data not shown), suggesting
hat as centers became more facile with the study and
onsent process, more donors successfully partici-
ated. Combining the consent for the clinical BM
ersus PBPC trial with the donor experience study was
one to simplify the consent process. Although each
enter had institutional review board–approved con-
ent forms that differed on the basis of local require-
ents, in general there was no option in the consent
orm that clearly indicated to donors that they could
articipate in the clinical trial without participating in
he donor experience study. As a result, donors may
ave agreed to participate to provide a graft for their
ibling but may not have been committed to the donor
xperience study. Under this circumstance, we would
ave expected the BM donors to be less likely to
ollow through with participation, because they were
ndergoing the standard donation process. Although
he higher degree of predonation anxiety in PBPC
onors supports that they were aware of the develop-
ental nature of the PBPC donation procedure, it
eems unlikely that PBPC donors who did not partic-
pate failed to do so because they were too distressed
o complete the study questionnaires.
In addition to securing adequate funding to sup-
ort the study, future studies could address the par-
icipation rate in 2 ways. Separating the donor expe-
ience consent from the main trial consent may give a
ore realistic expected participation rate. In that sit-
ation, a short questionnaire could be developed for
hose who decline to participate, to explore the rea-
ons for their choice. Postdonation participation was
robably not compromised by the time required to
omplete the questionnaires, because neither the
F-36 nor the POMS is lengthy, and the additional
rocedure-speciﬁc questions numbered 10 for each
roup. This would also not explain the differential
nitial participation between PBPC and BM donors.
lthough several attempts were made to obtain re-
ponses, the absence of ﬁnancial support for the study
ay have limited the amount of time coordinators
ould spend tracking down outstanding question-
aires.
Despite the limited number of responses, the sam-
le is probably representative of the larger group,
ecause there were no identiﬁable demographic dif-
erences between donors who participated and those
ho did not. For example, the response rate could not
e explained by age, because donors aged 60 years
esponded at a similar rate and with a similar range of
xperience as younger donors. Nor could postdona-
B&MTion participation be explained by the recipient expe-
ience up to day 30 after transplantation. Donors
hose siblings died by day 30 after transplantation
esponded at a similar rate to those whose siblings
ere still alive (data not shown). Also supporting the
epresentativeness of the responders was the balance
f positive and negative comments when donor nar-
atives were reviewed.
Many issues remain to be clariﬁed regarding the
elative efﬁcacy of mobilized PBPC versus BM as the
raft source for allogeneic transplant recipients in a
ariety of clinical settings. Although our study identi-
ed differences in the donor experience, donating
ither mobilized PBPC or BM is safe and generally
ell tolerated. Donor experience should not be the
rimary factor determining the graft source for allo-
eneic transplants.
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